By the end of 2023, the pharmaceutical company will have the addition of the trusted, green and gold kangaroo on half their Australian-made medicine products, a win for Australia’s medicine industry.
Sydney, 26 October 2023 – Viatris Australia, a subsidiary of Viatris Inc., a global healthcare company, today announced the addition of the famous green and gold kangaroo Australian Made, Australian Grown (AMAG) logo to its Australian medicine products. As a leading manufacturer of high-quality medicines in Australia, Viatris intends to have all of its products produced in Australia for the Australian market bear the AMAG logo. Almost 50 products manufactured in Carole Park, Queensland, now showcase the logo, with that number set to increase to half of its locally made products by the end of 2023. This scale will be a first for a prescription medicine manufacturer in Australia.
Viatris’ state-of-the-art manufacturing facility at Carole Park is one of the largest pharmaceutical manufacturing sites in Australia, capable of manufacturing approximately 4 billion doses of high-quality medicines for Australia and over 40 export markets. As a company, Viatris integrates global and local manufacturing networks to leverage collective expertise to connect people to products, avoid disruption and provide people everywhere with access to critical medicines.
“Although Australia has recently experienced reduced manufacturing capabilities across many industries, Viatris Australia is proud that our local manufacturing capability creates increased and resilient capacity for the production and supply of high-quality medicines. We are delighted to now include the Australian Made logo on our locally manufactured and sold products to symbolize our investment in Australia,” said Viatris Australia Country Manager, Sylvain Vigneault.
Products bearing the AMAG logo will include medicines across more than 10 major therapeutic areas covering a wide variety of noncommunicable and infectious diseases, ranging from cardiovascular health, antidepressants to well-known antibiotics.
“We are proud that our medicines for Australia will carry the Aussie Made logo. At Viatris our commitment to producing high-quality medicines is embraced across our entire global network which, in turn, supports building a resilient supply chain to reach more patients,” said Rob Elliot, Head of Operations ANZ.
“This is a commendation to our colleagues at Carole Park who are dedicated to producing high-quality medicines, furthering our mission to empower people worldwide to live healthier at every stage of life. We look forward to adding the logo to more of our locally made, locally-supplied products and continually celebrating our role in Australia,” said Mr. Elliot.
Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life's moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai, and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on Twitter, LinkedIn, Instagram, and YouTube.